VKTX catalyst watch- The first week in November should be very important as we will get additional phase 1 data on oral VK2735 at Obesity Week (doses of 60mg, 80mg and 100mg/day top line info plus info on lipids, etc. on the smaller dose to 40mg). Top line data for the higher doses should show more AEs and higher weight loss but pk data is more important in my view. Other competing compounds in the space will undoubtedly providing additional updates as well and that has moved the VKTX considerably. In the distant past , competitive updates have moved VKTX noticeably lower when big pharma and others just released top line weight loss data, however in the last month or so as competing compounds progress and release more AE data, Viking has moved up nicely.
In addition to Obesity Week in Nov., we will get 3rd Q Earnings after the close Oct 23rd approximately 2 weeks earlier. Lots of progress updates (maybe timing/design on ph3 for VK2735 or CDMO partner update or could hear positive VK2809 news with regard to ph3 trial design/partner interest.)
Some chance we will get data on VK0214 for the Ph1 trial on the rare disease X-ALD with earnings. This trial has taken an excessively long time to enroll which I consider to be a bad sign but there does not appear to be any expectations here so the downside is limited. (I'd be a buyer on any dip as the value in this stock is almost entirely VK2735 in obesity.) On the other hand, positive news on VK0214 could drive the valuation noticeably higher.
I'm expecting some increased volatility very near term. (Options premiums are very high on this stock.)
"People are best convinced by reasons they discover themselves"
AI
